ReviewAmerican journal of translational research2024
Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis.
Review in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- The combination of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors: a narrative review of existing meta-analysis.Acta diabetologica · 2026Review
- Metabolic and renal effects of combined SGLT-2 inhibitors and GLP1-R agonists therapy in type 2 diabetes: a real-world analysis across DKD and non-DKD patients.Journal of endocrinological investigation · 2026Article
- Review
- Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of combining GLP-1 receptor agonists (GLP-1RA) with SGLT-2 inhibitors (SGLT-2i) in elderly patients with type 2 diabetes mellitus (T2DM).
methodsA comprehensive search of Web of Science, Cochrane Library, Embase, and PubMed was conducted from inception to May 2024. Eligible randomized controlled trials (RCTs) assessing the efficacy of GLP-1RA combined with SGLT-2i for managing T2DM in elderly patients were included. Data extraction and quality evaluation were performed on eligible studies, and meta-analysis was conducted using RevMan 5.3 software.
resultsThis meta-analysis included 15 studies with a total of 11,679 elderly T2DM patients. The combined GLP-1RA and SGLT-2i therapy significantly improved several clinical outcomes. Hemoglobin A1c (HbA1c) levels were significantly reduced (mean difference [MD] -0.26; 95% confidence interval [CI] -0.32, -0.20; P < 0.0001), indicating effective glycemic control. Renal function, as measured by estimated glomerular filtration rate (eGFR), improved significantly (MD 2.18; 95% CI 1.56, 2.80; P < 0.0001), suggesting renoprotective effects. Lipid profiles also showed improvement, with reductions in LDL cholesterol (MD -0.56; 95% CI -0.64, -0.48; P < 0.0001) and increases in HDL cholesterol (MD 0.18; 95% CI 0.14, 0.22; P < 0.0001). Additionally, systolic blood pressure decreased significantly (MD -3.15 mmHg; 95% CI -4.72, -1.58; P < 0.0001). The combination therapy did not increase the risk of hypoglycemia or other adverse events compared to monotherapy, demonstrating a favorable safety profile. These results support the potential of combined SGLT-2i and GLP-1RA therapy as a comprehensive treatment approach for improving metabolic and cardiovascular health outcomes in elderly T2DM patients.
conclusionCombining GLP-1RA with SGLT-2i provides superior benefits over monotherapy in elderly T2DM patients, particularly for glycemic control, weight management, and cardiovascular protection. This combination also demonstrates a positive safety profile, making it a viable option for clinical use. Ongoing research into the long-term effects and mechanisms of this therapy is necessary to optimize and personalize treatment for elderly patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.